SCHEMBL14830109

SCHEMBL14830109

O=C(ON1CCOCC1c1ccccc1Oc1ccccc1)C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.35
▸ HPGD P15428 1/20 0.35
▸ KDM1A O60341 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ HTR1A P08908 1/20 0.34
▸ SLC6A2 P23975 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34
▸ SLC6A3 Q01959 1/20 0.34
▸ SCN1A P35498 1/20 0.34
▸ SCN2A Q99250 1/20 0.34
▸ SCN3A Q9NY46 1/20 0.34
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ GAA P10253 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ TSHR P16473 3/20 0.33
▸ TP53 P04637 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14829651 0.84 ALDH1A1 (0.41) ALDH1A1HPGDHSD17B10SCN3AMEN1
SCHEMBL14839981 0.82 TRPV1 (0.35) ALDH1A1MEN1KMT2ASMN1; SMN2BACE1
SCHEMBL14829350 0.81 BACE1 (0.39) ALDH1A1HPGDGAASMN1; SMN2TSHR
SCHEMBL14839957 0.72 TRPV1 (0.35) —
Trifluoroacetic Acid SCHEMBL14830108 0.70 SLC6A2 (0.41) KDM1AHTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL14839755 0.65 CHRM2 (0.36) ALDH1A1HPGDTSHR
SCHEMBL6943077 0.65 BACE1 (0.41) ALDH1A1HPGDGAASMN1; SMN2TSHR
SCHEMBL28239603 0.64 MAOB (0.33) —
SCHEMBL11511479 0.63 FFAR1 (0.45) ALDH1A1HPGDKDM1AHTR1ASLC6A2
SCHEMBL6049177 0.62 HSP90AA1 (0.41) ALDH1A1SMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2751088-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2014-07-09 — — EP disclosed
US-8765751-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-07-01 — — US disclosed
US-20130089624-A1 Compounds Useful as Inhibitors of ATR Kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-11 — — US disclosed
WO-2013049719-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130089624-A1 Compounds Useful as Inhibitors of ATR Kinase ATR, CHEK1, PLK1 ALDH1A1 4297/4885HPGD 3898/4885KDM1A 2426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback